Cartesian Therapeutics (RNAC) Free Cash Flow (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Free Cash Flow data on file, last reported at -$22.2 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 8.36% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was -$77.4 million, a 135.99% decrease from a year earlier, with the FY2025 full-year figure at -$79.4 million, down 223.78% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$22.2 million, up from -$23.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for RNAC reached as high as $15.5 million in Q3 2024 and fell as low as -$24.2 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$12.4 million across 5 years, with a median of -$12.9 million in 2022.
• Across the five-year window, Free Cash Flow tumbled 303.89% in 2023 and surged 267.76% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$12.9 million in 2022, then tumbled by 80.93% to -$23.3 million in 2023, then jumped by 68.06% to -$7.5 million in 2024, then tumbled by 209.17% to -$23.1 million in 2025, then climbed by 3.87% to -$22.2 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$22.2 million in Q1 2026, -$23.1 million in Q4 2025, and -$15.0 million in Q3 2025.